^
Association details:
Evidence:
Evidence Level:
Sensitive: C3 – Early Trials
New
Source:
Title:

Final results from a phase II trial of CIMAvax-EGF and nivolumab as second-line (2L) therapy after platinum-based chemotherapy in advanced non-small cell lung cancer (NSCLC).

Published date:
05/25/2023
Excerpt:
Pts with previously treated, immunotherapy-naive advanced NSCLC received 2.4 mg C-E IM every 2 weeks(w) for 4 doses (loading phase) in combination with N 240mg IV every 2 w, then continued monthly maintenance C-E combined with N 240mg IV every 2 w....mOS, 1-yr and 3-yr OS for EGFR/ALK/KRAS wildtype pts was higher [31.7 months (90% CI 5.9, NR), 67% (90% CI 4, 84), 50% (90% CI 24,71), respectively) compared to KRAS mutated NSCLC [10.1 months (90% CI 6.5, 12.1), 29% (90% CI 6, 56), 0% (90% CI 1, 41), respectively]....Among pts who completed PP treatment, pts with KRAS wildtype NSCLC had the longest mOS observed.
Secondary therapy:
EGF-PTI
DOI:
10.1200/JCO.2023.41.16_suppl.9135
Trial ID: